Gait analysis reveals new outcome measures for monitoring disease progression in individuals with late-onset Pompe disease.
Mireia Claramunt-Molet, Jordi Pegueroles, Ariadna Pi-Cervera and 10 others
PMID 41803906WHAT IT FOUND
Wearable sensors detected gait changes in Pompe disease that the standard six-minute walk test missed.
Half of patients judged stable by the walk test showed progression on this new index, suggesting it may catch decline earlier in clinical monitoring.
Key findings
01The new gait index identified progression in four participants who were classified as stable by the six-minute walk test.
02Patients with Pompe disease showed distinct gait abnormalities compared to healthy controls, including lower cadence, increased stance time, and greater deviation from normal kinematic patterns.
03The gait index successfully distinguished patients from healthy controls with high accuracy in the test set, outperforming the six-minute walk distance.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The sample size was small, with only 24 patients and 39 controls. The study was conducted at a single site and patient association meetings, which may limit generalizability. The Pompe-MDPI has not yet been validated in large-scale multicentric studies. Two patients used assistive devices during testing, which may influence gait kinematics. The control group was matched for age and velocity, but other factors could still confound results.
Declared interests
The study was funded by Generalitat de Catalunya and Centro para el Desarrollo Tecnológico Industrial. The authors used a proprietary system (Ephion Mobility) and developed the analysis pipeline using custom Python code by Ephion, suggesting a potential conflict of interest with the technology provider.
The easy way to misread this
Do not assume the Pompe-MDPI is ready for clinical use or that it definitively detects progression earlier than the 6MWT. The study was small, the index was developed and validated on the same limited dataset, and the authors explicitly state it needs validation in large multicentric studies before being accepted as an outcome measure.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →